Indications
Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status ? 2.
Composition
- Active substance
- vinflunine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Javlor
- Active substance
- vinflunine
- ATC code
- L01CA05
- Therapeutic area
- Carcinoma, Transitional Cell, Urologic Neoplasms
- Marketing authorisation holder